Roughly 30% of people with ADHD either don't respond to stimulants or can't tolerate them. Non-stimulant medications fill that gap. They work differently, take longer to kick in, and generally produce smaller effect sizes - but for certain patients, they're the better option.
There are four FDA-approved non-stimulant medications for ADHD: atomoxetine, guanfacine extended-release, clonidine extended-release, and viloxazine. A fifth, bupropion, is used off-label. Each targets different receptor systems in the prefrontal cortex.
Atomoxetine (Strattera)
Atomoxetine was the first non-stimulant approved for ADHD. It's a selective norepinephrine reuptake inhibitor (NRI) - it blocks the presynaptic norepinephrine transporter (NET), increasing synaptic norepinephrine concentrations.
There's an important nuance here. In the prefrontal cortex, NET also transports dopamine. The PFC has very low dopamine transporter (DAT) density, so most dopamine clearance happens through NET. By blocking NET, atomoxetine indirectly raises dopamine levels in the PFC specifically - without flooding the striatum the way stimulants do.
Guanfacine Extended-Release (Intuniv)
Guanfacine is a selective alpha-2A adrenoceptor agonist. This is a fundamentally different mechanism from atomoxetine or stimulants. It doesn't increase dopamine or norepinephrine concentrations at all. Instead, it works downstream.
Alpha-2A receptors sit predominantly on the dendritic spines of pyramidal neurons in the prefrontal cortex. When guanfacine activates these receptors, it closes HCN (hyperpolarization-activated cyclic nucleotide-gated) channels. This strengthens PFC network connectivity - improving signal-to-noise ratio for focused attention. Think of it as turning up the clarity of existing catecholamine signalling rather than flooding the system with more neurotransmitter.
Clonidine Extended-Release (Kapvay)
Clonidine is also an alpha-2 agonist, but non-selective - it hits alpha-2A, 2B, and 2C subtypes. Alpha-2A is predominant in PFC (attention), alpha-2B in the thalamus (arousal), and alpha-2C in emotional regulation circuits.
Viloxazine (Qelbree)
Viloxazine is a serotonin-norepinephrine reuptake inhibitor (SNRI) approved for ADHD in 2021. It has higher affinity for NET than SERT and also modulates serotonin receptor activity - specifically acting as a 5-HT2B antagonist and 5-HT2C inverse agonist. This serotonergic activity indirectly increases prefrontal dopamine and norepinephrine.
Bupropion (Off-Label)
Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI) approved for depression and smoking cessation. It increases both dopamine and norepinephrine in the PFC - mechanistically similar to stimulants but weaker.
It's not FDA-approved for ADHD. The evidence base is limited to small trials. Effect sizes are generally smaller than approved non-stimulants. However, it can be useful when a patient has comorbid depression and ADHD, and the clinician wants to treat both with a single medication. It has the advantage of also reducing nicotine cravings - relevant given that ADHD individuals are twice as likely to use nicotine.
Comparative Efficacy
Network meta-analysis data ranks ADHD medications by clinician-rated efficacy (SMD):
| Medication | SMD | Class |
|---|---|---|
| Amphetamines | −1.02 | Stimulant |
| Methylphenidate | −0.78 | Stimulant |
| Clonidine ER | −0.71 | Non-stimulant |
| Guanfacine ER | −0.67 | Non-stimulant |
| Atomoxetine | −0.56 | Non-stimulant |
When Non-Stimulants Are Preferred
There are six clinical scenarios where non-stimulants become the first-line consideration:
- Stimulant non-response - approximately 30% of patients don't adequately respond to stimulants
- Intolerable side effects - insomnia, appetite suppression, anxiety, or cardiovascular effects from stimulants
- Comorbid tics or Tourette syndrome - atomoxetine, guanfacine, and clonidine all reduce tic frequency
- Substance abuse risk or diversion - non-stimulants are not controlled substances
- Comorbid anxiety - atomoxetine is particularly effective here; stimulants can worsen anxiety
- Need for 24-hour coverage - atomoxetine and alpha-2 agonists provide all-day effect without the evening rebound seen with some stimulant formulations
Combination Therapy
The most common combination is guanfacine plus a stimulant. The evidence supports this: complementary mechanisms, opposing cardiovascular effects (improving tolerability), extended duration of coverage, and potentially better symptom control than either alone. Clonidine plus stimulant is also used, especially for patients with tics. Atomoxetine plus stimulant has less evidence but is tried in treatment-resistant cases.
Practical Clinical Notes
From the Stanford clinical literature: start low, go slow - especially with alpha-2 agonists. Monitor blood pressure, heart rate, weight, and sleep. Don't discontinue too early - atomoxetine needs 12 weeks, alpha-2 agonists need at least 2 weeks. Dose is not determined by age, weight, or symptom severity - it's entirely individual. Consider the patient's full clinical picture: sleep problems, appetite, tic history, substance use history, and cardiovascular baseline.
References
- Cortese S, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727-738.
- Arnsten AFT, Jin LE. Guanfacine for the treatment of cognitive disorders: a century of discoveries at Yale. Yale J Biol Med. 2012;85(1):45-58.
- Stanford University. New Discoveries in the Behavioral Neuroscience of Attention-Deficit Hyperactivity Disorder (Chapter on Non-Stimulant Pharmacotherapy).
- Faraone SV. The pharmacology of amphetamine and methylphenidate. Neurosci Biobehav Rev. 2018;87:255-270.
- Yu C, Garcia-Olivares J, et al. Viloxazine: mechanism of action and clinical implications. Curr Psychiatry Rep. 2022;24:873-884.